Wednesday 17 January 2018 ShareProphets: The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Broker Hybridan says Optiobiotix at 19.875p is worth 48.9p or 200p

By Tom Winnifrith | Tuesday 17 February 2015

Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Lets be upfront, RMPC owns this shares and since I often say that all brokers notes are worthless piffle I cannot make an exception here. However broker Hybridan has initiated its coverage of Optibiotix (OPTI) with a very bullish assessment indeed.

It writes: We have valued OptiBiotix by the sum of its parts, assessing the company’s development pipeline’s ability to capture share of the enormous markets they address, and where appropriate citing relevant recent corporate transactions. Based on relatively conservative assumptions, our valuation suggests a current valuation of £153.5m which we have discounted by a further 75% reflecting the early stage of its product pipeline. This suggests an indicative valuation of £39.6m or 48.9p per share on a fully diluted basis, some 145% above the current price.

Whatever. You can read the full note HERE

Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on OPTI



  1. It might well say that Tom ……….. but the footer on the broker note says clearly :-

    “The Investment Analyst who is responsible for the preparation of this Investment Research is an employee of Hybridan that has been
    engaged by Hybridan LLP to produce this document.
    Research recommendations:
    In line with our conflicts of interest policy Hybridan LLP does not produce recommendations or publish target prices on companies who
    are corporate clients of Hybridan LLP

    Many people also forget that broker target prices are normally a 12 month forward Target price and not intended as the indicated value of today .

    Having said that ……… great share and great tip ………. but not 49p or 200p great at this stage ! Dont put the ranch on it .

  2. Tom, what are your own personal predictions for this one?

  3. TraseEntranceOnly

    That’s a very bullish note from the broker. On top of this note I see that today OPTI have released an RNS to announce the appointment of Jim Laird as Commercial Director, which looks to be a very promising appointment.

Enter your comment below. Fields marked * are required. You must preview your comment first before finally posting.

Site by Everywhen